IRCT20190717044241N3 IRCT 2020-12-31 Barakat Pharmaceutical Group Cell therapy in patients with COVID-19 Cell therapy in patients with COVID-19 using mesenchymal stem cells: Phase 2 clinical trial 2020-12-21 anticipated 20 Complete https://irct.ir/trial/52820 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization was used for achieving equal sample sizes in each group. For example, in intervention (I)/control (C) comparison, the process involved recruiting participants in short blocks and ensuring that half of the participants within each block were allocated to the ‘‘I’’ group and the other half to the ‘‘C’’ group. Within each block, however, the order of patients was random. We considered size 4 blocks. If I/C is represented by I/C methods, there would be 6 different ways in which 4 patients can be split evenly between 2 methods, Blinding description: There are the same cell bags for infusion during the study. Cleanroom staff, DSMB, and data statisticians just aware of their contents. 2 COVID-19. Intervention 1: Intervention group: Patients with coronavirus 19 who undergo mesenchymal stem cell transplantation at a rate of 2 million per kilogram body weight (based on IBW) through peripheral blood (IV)on days 0, 3, and 6. Intervention 2: Control group: Participants with COVID19 receiving routine and placebo treatment (based on IBW) intravenously on days 0, 3, and 6. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no additional data.